Abatacept Delays Onset of Rheumatoid Arthritis
A promising new study suggests rheumatoid arthritis may not be as inevitable as once thought for people at high risk.
A promising new study suggests rheumatoid arthritis may not be as inevitable as once thought for people at high risk. Researchers found that just one year of treatment with the immune-targeting drug abatacept delayed the onset of rheumatoid arthritis by up to four years, with benefits lasting long after treatment ended.